AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04835662 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Complementary feeding promotion
Description: The intervention engaged fathers through community meetings, religious services, and mobile phone text and voice messages. Mothers received home visits from community health extension workers (CHEWs), which fathers also could attend. Social behavior change communication materials included TV and radio messages, sermon guides, counseling cards, pamphlets, posters, and feeding bowls.
Study NCT03195621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent implantation
Description: Stent placement after risk factors assessment plus FFR or ultrasound or OCT detection for critical lesions.
Study NCT00423332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 45 mg oral tablet
Study NCT00423332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cediranib Placebo
Description: oral tablet
Study NCT01737710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Intradermal Vaccine
Description: A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
Study NCT01737710 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (Intramuscular) vaccine
Description: A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
Study NCT03318978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene
Description: Oral micro-dose range (25, 50, 100 and 250 ng)
Study NCT02185118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: 1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
Study NCT02185118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
Study NCT02185118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: 1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
Study NCT03789760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SaiLuoTong capsule
Description: 500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
Study NCT03789760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 500 subjects are randomly divided into two groups by 3:1. 125 subjects in the control group take two pills(120mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
Study NCT02504242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inject BMP
Study NCT02504242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locally Harvested Bone
Study NCT03786328 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Psychiatric Treatment
Description: Standard psychiatric treatment is offered individuals identified with a clinical mental disorder. Treatment will follow golden standard treatment in the psychiatric clinic, meaning a combination of therapy and psychopharmacological treatment.
Study NCT03786328 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preventive Psychological Treatment
Description: Preventive Psychological Treatment is offered individuals identified with a sub-clinical mental condition. Treatment consists of 8 sessions of cognitive-behavioural therapy.
Study NCT03383289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R-REM training
Description: three training modules for front-line long-term care staff to aid in recognition, management and reporting of R-REM
Study NCT01672801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT01672801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: oral administration
Study NCT04752709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELITONE UUI
Description: External electrical stimulation
Study NCT04752709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELITONE UUI
Description: External electrical stimulation
Study NCT00746889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: single intraarticular injection of 40 mg of triamcinolone acetonide
Study NCT00746889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Single intraarticular injection of 1 ml of 0.9% saline
Study NCT02890576 — intervention group
Intervention type: OTHER
Intervention: telemedicine
Description: Monitoring of patients with cochlear implant with sessions of telemedicine
Study NCT03058562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: ABX-1431, capsules, 40 mg in the fasting state
Study NCT03058562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Matching Placebo
Study NCT03058562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: ABX-1431, capsules, 20 mg with a high fat meal
Study NCT03569930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flavonoid-based supplements
Description: Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
Study NCT01556685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical and neurological evaluation
Description: The day of the usual IFN beta 1a IM injection
Study NCT01556685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample
Description: For evaluation of interferon-related Nab
Study NCT03569930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centella Complex
Description: The components are: Centella Asiatica, Beta-glucan, Arnica, Aloe Vera, Menthol, Devil's claw, perform actions useful to alleviate the painful symptomatology, restore the tone of the venous wall, assist the treatment of microcirculatory damage.
Study NCT03569930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard of care
Description: diet rich in water and vegetable fibers, hygienic and anal dilator
Study NCT01556685 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample
Description: genetic evaluation - predisposition to Nab generation
Study NCT02162329 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit.
Study NCT02162329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit.
Study NCT02162329 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalography (EEG)
Description: Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.
Study NCT02162329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.
Study NCT02162329 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (fMRI
Description: Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit.
Study NCT02508077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02508077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02508077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02508077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO
Study NCT02508077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT01130376 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GTU-MultiHIV B clade vaccine1mg
Description: Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
Study NCT01130376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-MultiHIV B clade vaccine1mg
Description: Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
Study NCT01130376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: 5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
Study NCT01130376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
Study NCT02162329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (fMRI
Description: Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit.
Study NCT01130376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: 150 ug administered subcutaneously once daily 4 hours from IL-2 injections
Study NCT01130376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 150 ug administered subcutaneously once daily 4 hours from IL-2 injections
Study NCT01130376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: 4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
Study NCT01130376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: 4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
Study NCT04471857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Study NCT04806711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menicon Z Night
Description: Menicon Z Night orthokeratology contact lenses were used to assess their efficacy in reducing myopia progression in children
Study NCT04806711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Distance, single-vision glasses were used as a control
Study NCT03136640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study NCT00957320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
Study NCT04573387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operation
Description: All participants are treated with burr-hole craniotomy and a drainage system as follows. Participants undergo surgical procedure under local anesthesia in the hemisphere with a lateral position, but general anesthesia is performed when participant cannot tolerate the operation. A single 1.5 cm burr hole is drilled over the maximum width of the hematoma cavity. After coagulating with bipolar diathermy, dura mater is opened with a cruciate incision. A soft catheter is placed carefully in all directions of the hematoma cavity for irrigating subdural collections with 1,000 mL warm Ringer's lactate saline until clarification. The drainage catheter is inserted ½ length of the maximum diameter of the hematoma cavity toward the frontal region. After the skin is closed, the catheter was connected to a soft collection bag that is placed under the head for passive drainage. During the drainage period, participants stay in bed until the drain is removed.
Study NCT04573387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operation
Description: All participants are treated with burr-hole craniotomy and a drainage system as follows. Participants undergo surgical procedure under local anesthesia in the hemisphere with a lateral position, but general anesthesia is performed when participant cannot tolerate the operation. A single 1.5 cm burr hole is drilled over the maximum width of the hematoma cavity. After coagulating with bipolar diathermy, dura mater is opened with a cruciate incision. A soft catheter is placed carefully in all directions of the hematoma cavity for irrigating subdural collections with 1,000 mL warm Ringer's lactate saline until clarification. The drainage catheter is inserted ½ length of the maximum diameter of the hematoma cavity toward the frontal region. After the skin is closed, the catheter was connected to a soft collection bag that is placed under the head for passive drainage. During the drainage period, participants stay in bed until the drain is removed.
Study NCT04573387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-time drainage
Description: All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. The drainage will be removed after 48 hours.
Study NCT04573387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exhaustive drainage
Description: All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. If the computed tomography (CT) scan on the first day after surgery indicates that the affected brain region shows sufficient re-expansion, the drainage catheter will be removed when drainage ceases. If subdural collections remain in the hematoma cavity, the participant will be treated with 30,000 U urokinase injection into the hematoma cavity through the catheter. The catheter will be closed and reopened in 1.5-2 hours, and a CT scan will be performed when drainage ceases. If the CT scan shows sufficient re-expansion of the brain, the catheter will be removed. However, if the brain does not show good re-expansion and there is still a residual subdural collection, the above steps will be repeated. If the participant is subjected to urokinase injection for 3 times, the catheter will be removed when drainage ceases.
Study NCT04573387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative computed tomography
Description: All participants undergo a CT scan before the drain is removed, and the last CT scan will be performed before the patient is discharged from the hospital.
Study NCT04573387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative computed tomography
Description: All participants undergo a CT scan before the drain is removed, and the last CT scan will be performed before the patient is discharged from the hospital.
Study NCT03896035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention Group
Description: The behavioral intervention is designed for older Veterans with cLBP and depression and will include 8 individual telephone sessions delivered by health coaches over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
Study NCT00687037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride
Study NCT03902379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive CCI intervention
Study NCT03902379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03902379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03902379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02315326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A.
Study NCT02315326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD- Methotrexate (MTX)
Description: Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
Study NCT02315326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab + HD- Methotrexate (MTX)
Description: Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
Study NCT02315326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine
Description: Arm D: THIS IS THE ONLY ARM RECRUITING: : Oral procarbazine (100mg/m2/day) will be given on Day 1 through 7 during each cycle. Patients will be maintained on a tyramine-free diet during procarbazine administration.
Study NCT01183676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEPAKOTE® Tablets, 500 MG
Description: 1 x 500 mg Tablet, under fed conditions
Study NCT01183676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
Description: 1 x 500 mg Tablet, under fed conditions
Study NCT00957476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fish Oil
Description: 800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
Study NCT00957476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Fish Oil
Description: 800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
Study NCT02162329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Classes
Description: Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.